Spots Global Cancer Trial Database for subcutaneous
Every month we try and update this database with for subcutaneous cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels | NCT00083928 | Ovarian Cancer Primary Periton... | Å6 subcutaneous... | 18 Years - | Ångstrom Pharmaceuticals | |
| Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens | NCT01695330 | Multiple Myelom... | Subcutaneous bo... | 18 Years - | Oncotherapeutics | |
| A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread | NCT04810078 | Clear Cell Rena... | Nivolumab and r... Nivolumab | 18 Years - | Bristol-Myers Squibb | |
| A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors | NCT02573259 | Part 1 MELANOMA SCCHN OVCA SARCOMA OTHER SOLID TUM... Part 1 and 2 NSCLC UROTHELIAL CARC... | PF-06801591 PF-06801591 | 18 Years - | Pfizer | |
| Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia | NCT00328198 | B-Cell Chronic ... | Alemtuzumab Alemtuzumab | 18 Years - | Sanofi | |
| Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens | NCT01695330 | Multiple Myelom... | Subcutaneous bo... | 18 Years - | Oncotherapeutics | |
| VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis | NCT01390545 | Rheumatoid Arth... | Veltuzumab | 18 Years - | Takeda | |
| Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors | NCT00085878 | Solid Tumor Can... | SB-485232 | 18 Years - | GlaxoSmithKline | |
| Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels | NCT00083928 | Ovarian Cancer Primary Periton... | Å6 subcutaneous... | 18 Years - | Ångstrom Pharmaceuticals | |
| Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China | NCT01812096 | Multiple Myelom... | Subcutaneous bo... Intravenous bor... | 18 Years - | The First Affiliated Hospital of Soochow University | |
| Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous Cancer | NCT00198276 | Cancer | MedPulser Elect... | 18 Years - | Inovio Pharmaceuticals | |
| Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy | NCT00800943 | B-Cell Chronic ... | Alemtuzumab (Ca... | 18 Years - | Chronic Lymphocytic Leukemia Research Consortium | |
| Ertapenem Administered Subcutaneously Versus Intravenously | NCT03218800 | Urinary Tract I... | Ertapenem | 18 Years - | Instituto Nacional de Cancer, Brazil | |
| A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors | NCT02573259 | Part 1 MELANOMA SCCHN OVCA SARCOMA OTHER SOLID TUM... Part 1 and 2 NSCLC UROTHELIAL CARC... | PF-06801591 PF-06801591 | 18 Years - | Pfizer | |
| Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy | NCT00800943 | B-Cell Chronic ... | Alemtuzumab (Ca... | 18 Years - | Chronic Lymphocytic Leukemia Research Consortium | |
| Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens | NCT01695330 | Multiple Myelom... | Subcutaneous bo... | 18 Years - | Oncotherapeutics | |
| Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China | NCT01812096 | Multiple Myelom... | Subcutaneous bo... Intravenous bor... | 18 Years - | The First Affiliated Hospital of Soochow University | |
| Velcade (Bortezomib) Consolidation After Transplant | NCT01539083 | Multiple Myelom... | Thalidomide Bortezomib Cyclophosphamid... Dexamethasone Prednisolone | 18 Years - | Janssen Scientific Affairs, LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
